<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Neurology</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9B8C6561-A7B1-4005-94C5-F62552C54593"><gtr:id>9B8C6561-A7B1-4005-94C5-F62552C54593</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Lovestone</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62211B96-56AF-4672-8BA7-754E3F0AC07B"><gtr:id>62211B96-56AF-4672-8BA7-754E3F0AC07B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/05BF89CB-F4A6-4BD3-A566-CA7B0792F3B4"><gtr:id>05BF89CB-F4A6-4BD3-A566-CA7B0792F3B4</gtr:id><gtr:firstName>Safa</gtr:firstName><gtr:surname>Al-Sarraj</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900635"><gtr:id>0D1FF662-D2F2-45FB-802C-1BA260079797</gtr:id><gtr:title>London Neurodegenerative Diseases Brain Bank (LNDBB) : a national resource for the neuroscience research community</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900635</gtr:grantReference><gtr:abstractText>The Brain Bank collects post-mortem brain tissue from persons with neurodegenerative diseases, such as dementia and motor neuron disease. Wherever possible data from previous clinical presentations, neuropsychological tests and neuroimaging are also collected. The brain tissue is examined by neuropathologists and illness is diagnosed according to internationally agreed criteria. Samples of brain tissue in various fixation states, such as frozen and formalin-fixed, are then made available to Neuroscience research centers along with, where available, spinal cord tissue and cerebrospinal fluid. 
The purpose of the project is to provide clinically studied and pathologically verified brain tissue to facilitate and promote internationally competitive research into Neurodegenerative disease.
The Brain Bank aims are to fulfill international recommendations and guidelines with regard to brain tissue banking. As such, this involves the systematic and focused collection of well-characterised post-mortem material and its subsequent distribution to research groups both regionally and nationally. This will necessarily underpin high quality and peer-reviewed research. 
The following is a summary of the key functions of the Brain Bank: 
1. To advance the understanding of, and facilitate research into the underlying causes of neurodegenerative and neurological diseases through the provision of clinically and neuropathologically well-characterised brain tissue to the research community. 
2. To facilitate brain donation through an ethically approved programme of informed consent for cohort studies and ad-hoc donation.
3. To provide pathological diagnosis to the relatives of brain donors according to best national and international protocols.
4. To coordinate the processing and dissemination of well-preserved brain tissue for clinical, biochemical, molecular pathology, genetic and transcriptional research projects, and maintain an open door policy of responding to requesters without prejudice.
5. To ensure ?donor care? and keep contact with ?brain donor? families, informing them about diagnosis and progress in research.
6. To disseminate and promote knowledge of brain banking through scientific meetings, public open days, collaboration with charities and MRC newsletters.
7. To provide professional teaching, training, information and educational resources for neuroscientists.
8. To facilitate collaboration between basic research scientists, pathologists and clinicians to promote transitional research to help develop new diagnostic and therapeutic strategies for brain diseases.
9. To maintain gold standards of excellence in Brain Banking for storage of frozen and formalin-fixed brains.
10. To follow most recent ethical principles for best practice in Brain Banking, from recruiting donors and consent for postmortem to tissue requests and follow strictly the guidelines of the Human Tissue Act.</gtr:abstractText><gtr:technicalSummary>Clincally and neuropathologically assessed and characterised human post-mortem brain tissue is one of the most important resources for research in neurodegeneration. Continued access to tissue is vital for the further development of research strategies and future treatments. There has been significant research progress during the last three decades, which has increased demand for high quality brain tissue from brain banks. The London Neurodegenerative Diseases Brain Bank at the IoP has become a leader in the field of brain banking and a major source of high quality brain tissue not only for researchers at the IoP and elsewhere in London but throughout the UK and worldwide and has thus contributed to the success of many research studies. Material from the Brain Bank is also essential for the success of on-going research programmes. The aim of the Brain Bank is to achieve the gold standard in brain banking by programmed brain donation, including regulated ad-hoc donations, following best practice in ethical matters relating to consenting, donor family care, high standards of storage of brain tissue and easy access to tissue for researchers. We aim to continue to focus our banking on neurodegenerative diseases including Alzheimer?s Disease, Motor Neurone Disease and movement disorders but to facilitate other smaller collections, such as psychosis, traumatic brain injury and paediatric disorders in order to enhance research in these areas. The ultimate goal is to contribute to understanding the mechanisms of neurodegeneration, in order to prepare the way for new scientifically based treatments and prevention as well as play an integral part in clinical studies and the evaluation of clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-11-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>427102</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F55ECBF6-C581-4A0D-92D9-AB7A65DFDBF2</gtr:id><gtr:impact>Brain Bank staff gave a talk as part of IOP open day on Neurodegeneration research - approx 100 people attended in small groups throughout the day.

More interest in and understanding of brain donation, more registrations.</gtr:impact><gtr:outcomeId>NmE8MCSTe3K</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture on motor neuron disease research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>736E6937-C82F-4652-9FB5-B5806EC1D6E4</gtr:id><gtr:impact>I spoke at a dinner hosted by the MND Association for major donors at the Royal Institution</gtr:impact><gtr:outcomeId>58c93ff0bc3547.27040784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to transplant coordinators</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6879CA4D-F899-4F5E-8372-972D3C43A59E</gtr:id><gtr:impact>15 Tissue transplant coordintors attended talk which emphasised importance and need for brain donation, the research produced and the practicalities involved

more referals from this route</gtr:impact><gtr:outcomeId>JeGq4ys3EoC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>323DAA23-4616-43C3-99A8-0D7160EE087C</gtr:id><gtr:impact>Public lecture on the genetics and biology of motor neuron disease</gtr:impact><gtr:outcomeId>58c93f4e8924f4.27061276</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biomedical Sciences Institute PhD Studentship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>55FA0ABE-7940-41D4-BBD6-6ADA75588016</gtr:id><gtr:outcomeId>58c93d5ceb05d9.47554176</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>D9B6741C-B98D-4555-9EFE-B4A06AC99D40</gtr:id><gtr:outcomeId>58c93dbea62219.99794471</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>427000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Grant - renewal of Brain Bank</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1D1EC67A-2DB3-41B1-B2DA-EFD0E3E54841</gtr:id><gtr:outcomeId>9557BA8C1000</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>91799BEE-EE82-4F16-9839-C7B0A652CC2A</gtr:id><gtr:title>Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c3f5a5bc7ae9744e72b93546e48cb6f"><gtr:id>7c3f5a5bc7ae9744e72b93546e48cb6f</gtr:id><gtr:otherNames>Ahmeti KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>544bcf016e38a3.28501419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A83B526-0D85-43E4-9669-CCBFD685E3C3</gtr:id><gtr:title>A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf02883315.60737102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14D3D3DA-9D6C-4A90-8E8D-0EC64927F58D</gtr:id><gtr:title>Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d46237ac4964.75802103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2639620-2389-46D4-AA81-3F59CBCD66F4</gtr:id><gtr:title>ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d46239d884c7.36960805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32E6840A-6EA0-4768-9D43-1DE8E035F2DB</gtr:id><gtr:title>Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5aa699e3687533.67844697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>072FAF21-549A-474C-A937-57A98FBB827A</gtr:id><gtr:title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da89c318f56fc7256d9d74b60d23229"><gtr:id>9da89c318f56fc7256d9d74b60d23229</gtr:id><gtr:otherNames>Sims R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5aa699e46a4a55.51168519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FB26EED-716C-4A7B-9EE7-5838B81DF413</gtr:id><gtr:title>The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a1becffcc1571868d22b707ce216d4c"><gtr:id>5a1becffcc1571868d22b707ce216d4c</gtr:id><gtr:otherNames>Wong CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d462397da5f1.15374831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6914DC62-2764-4499-9A2E-BE83A38C5C36</gtr:id><gtr:title>No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc23875dbdf591dfec98dd2283598bc3"><gtr:id>cc23875dbdf591dfec98dd2283598bc3</gtr:id><gtr:otherNames>Goris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544bcf0257e9b7.52663862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AADA348-F56F-4E43-9A43-F890401CFA4A</gtr:id><gtr:title>Compromised paraspeckle formation as a pathogenic factor in FUSopathies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1a410013657f0eb066eef4168175c03"><gtr:id>e1a410013657f0eb066eef4168175c03</gtr:id><gtr:otherNames>Shelkovnikova TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5462193fb18370.60456415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>039B398B-E36A-4CEB-BA47-55D92FD0EC00</gtr:id><gtr:title>Homozygosity analysis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5ecebb0a95326732850cb51e132dc6"><gtr:id>bb5ecebb0a95326732850cb51e132dc6</gtr:id><gtr:otherNames>Mok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf01c66b68.28467340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5811974B-4EC9-4236-A7C8-81BC321473ED</gtr:id><gtr:title>Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/648ce689029eb74519bb3610828d1173"><gtr:id>648ce689029eb74519bb3610828d1173</gtr:id><gtr:otherNames>van Eijk RPA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5aa699e5ebbea6.81534669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71546972-8C26-494E-A73C-AFDD04873259</gtr:id><gtr:title>Comment on &amp;quot;Drug screening for ALS using patient-specific induced pluripotent stem cells&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>544bcf01f119e7.52699369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5109961A-850E-4C05-8B42-6803E398C5DC</gtr:id><gtr:title>ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77bcf36f991f182856eac148a0a0aa02"><gtr:id>77bcf36f991f182856eac148a0a0aa02</gtr:id><gtr:otherNames>Stoica R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>544bcf042f8d38.13230496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DE2990B-9749-465B-BA14-D85448FDCEA1</gtr:id><gtr:title>Neuromuscular disease: new insights and avenues for therapy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544bcf019cb4a7.27593700</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>501092CA-D932-4ED6-BDA6-414561E4DEEC</gtr:id><gtr:title>A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2841aab396cd2b4f18a94e7a29ae23"><gtr:id>aa2841aab396cd2b4f18a94e7a29ae23</gtr:id><gtr:otherNames>Morgan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5aa699e3d49b28.83252519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85C2EFAA-7305-4197-B715-DCA764A17DBB</gtr:id><gtr:title>An evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional regulator and its association to ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3108c31a0519408ba70fe51961bbba10"><gtr:id>3108c31a0519408ba70fe51961bbba10</gtr:id><gtr:otherNames>Savage AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf03736d30.04611140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9D11029-E860-4967-B3AF-C17A762ED46B</gtr:id><gtr:title>The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aa73e328eb61ebd7307a45f0b5976b5"><gtr:id>9aa73e328eb61ebd7307a45f0b5976b5</gtr:id><gtr:otherNames>Martin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5aa699e4e53521.11586011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AE793F8-175F-421D-A9D4-B022DFAB8642</gtr:id><gtr:title>Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ecfd0497d0375c0a88359b331f4d279"><gtr:id>6ecfd0497d0375c0a88359b331f4d279</gtr:id><gtr:otherNames>Alami NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>544bcf031799a2.08217536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB0E429E-B215-46DE-9B4B-14A989E8C903</gtr:id><gtr:title>Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a46cc13f73dd87b9293e1cd22958c7c"><gtr:id>6a46cc13f73dd87b9293e1cd22958c7c</gtr:id><gtr:otherNames>Stepto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_540e16ae16a979aa1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49EFA0BE-6793-49AD-B805-C1C42485BDE1</gtr:id><gtr:title>TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>56d46237093897.21473834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C938612-8DBD-4D2C-B429-A432CC931A80</gtr:id><gtr:title>ATXN2 trinucleotide repeat length correlates with risk of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdc6e29ff1fbfb82d08db9aa811d9c11"><gtr:id>fdc6e29ff1fbfb82d08db9aa811d9c11</gtr:id><gtr:otherNames>Sproviero W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5aa699e29b59d1.36739737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA89687B-8EBE-4EE9-90C5-C09FA01B313C</gtr:id><gtr:title>C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>544bcf04854020.50255754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D7A697-B7E8-4A93-B027-7BDF92B03502</gtr:id><gtr:title>Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43.</gtr:title><gtr:parentPublicationTitle>Neuropathology : official journal of the Japanese Society of Neuropathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0919-6544</gtr:issn><gtr:outcomeId>d4LHNpTASTv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D17849F-FFFF-47DC-9CA7-386A6AA6DFDD</gtr:id><gtr:title>Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18061332c54aaf54ab04a4a898d17ccc"><gtr:id>18061332c54aaf54ab04a4a898d17ccc</gtr:id><gtr:otherNames>Gomez-Deza J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d46238c9a2f3.14235257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>390875F9-ED78-4868-B2FB-0D53091A94EF</gtr:id><gtr:title>Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52940ec2fe08219598d16e61c9f32c80"><gtr:id>52940ec2fe08219598d16e61c9f32c80</gtr:id><gtr:otherNames>Niblock M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56d4623a192be3.89588407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25BB8FE4-CEA8-46B0-8626-F53BA0B10163</gtr:id><gtr:title>Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>544bcf02dec130.64984146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85394061-08D0-4E9B-A300-EB9FB0BC6AC6</gtr:id><gtr:title>RNA Misprocessing in-Linked Neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9adb0cf9c748d2062adf63457cc15ba4"><gtr:id>9adb0cf9c748d2062adf63457cc15ba4</gtr:id><gtr:otherNames>Barker HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>5aa699e5738790.24080771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A59817E-3D1E-4747-8E44-9BB17752209A</gtr:id><gtr:title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>544bcf013e1c05.46260780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9B2F2A7-5904-4215-9BCC-BF9F958B1A2C</gtr:id><gtr:title>Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaff144eb8c549f75ef3e66c1e865ad2"><gtr:id>aaff144eb8c549f75ef3e66c1e865ad2</gtr:id><gtr:otherNames>Mitchell JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-5960</gtr:issn><gtr:outcomeId>56d462387668a0.03122193</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>012986DB-01C9-4DD4-9BCB-22A64E45AA5A</gtr:id><gtr:title>Unpicking neurodegeneration in a dish with human pluripotent stem cells: one cell type at a time.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>544bcf0229e0f0.81404388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>296ABD98-164B-405A-BBDB-8A76A972508C</gtr:id><gtr:title>Tar DNA-binding protein-43 (TDP-43) regulates axon growth in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0737bcb5a8ebef94755f6214dfe82972"><gtr:id>0737bcb5a8ebef94755f6214dfe82972</gtr:id><gtr:otherNames>Tripathi VB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>pm_540e16ae16aa32be5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4E13653-6320-4263-9293-52162194E368</gtr:id><gtr:title>Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>544bcf045a5fe5.17451079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D145500-3B9A-4779-90E3-800A0089D19D</gtr:id><gtr:title>A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac5f45d8a5f9965eb360b3f6697fe0a9"><gtr:id>ac5f45d8a5f9965eb360b3f6697fe0a9</gtr:id><gtr:otherNames>Akimoto C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>544bcf03a36e01.94761814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20E16B73-76C4-4CEC-ABE7-4BCED4860B60</gtr:id><gtr:title>Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a68fd5b1ddbc5cb477a04d8d9b44b0b"><gtr:id>3a68fd5b1ddbc5cb477a04d8d9b44b0b</gtr:id><gtr:otherNames>?talekar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>56d462377e5135.87427190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861AB33B-A257-405E-84DC-43918D0282D6</gtr:id><gtr:title>Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cd860059da8333022783d0f25c6f76b"><gtr:id>6cd860059da8333022783d0f25c6f76b</gtr:id><gtr:otherNames>Pidsley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>58de6a6c14c350.72562711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C20529E5-5095-42DF-9D21-EF63990FBC51</gtr:id><gtr:title>Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_540e16ae16a8e0adb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>070228D1-6E74-458E-97E5-8BF957933E94</gtr:id><gtr:title>Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544bcf00f13c98.09263733</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900635</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>